WuXi AppTec, a leading global pharmaceutical CRDMO, has been recognized in the FTSE4Good Index Series for the fourth consecutive year. This recognition underscores the company's ongoing dedication to sustainable practices.

The FTSE4Good Index Series, developed by FTSE Russell, evaluates companies on their sustainability efforts and serves as a guide for investors focused on responsible corporate behavior. In the latest evaluation, WuXi AppTec scored the maximum 5 points in areas such as Corporate Governance, Anti-Corruption, and Labor Standards.

Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of its Sustainability Committee, expressed pride in the achievement, noting it reflects market trust in the company's sustainable management. He emphasized continued efforts to promote responsible practices and support the pharmaceutical industry's sustainability, aligning with the vision of making every drug possible and treating every disease.

WuXi AppTec embeds sustainability into its operations as an innovator and partner in the pharma sector. Its efforts have earned high marks from various rating bodies, including AAA from MSCI, A List from CDP in multiple categories, Gold from EcoVadis, inclusion in Dow Jones Best-in-Class World Index and S&P Global Sustainability Yearbook, and Prime status from ISS ESG.

The company has had its near-term GHG reduction targets approved by SBTi. It participates in the UN Global Compact and partners with PSCI as a supplier.

About WuXi AppTec

WuXi AppTec serves as a key partner in pharmaceutical and life sciences, offering R&D and manufacturing services to drive healthcare advancements. Operating in Asia, Europe, and North America, it provides comprehensive CRDMO services. Working with partners in over 30 countries, it aims to deliver innovative treatments, committed to its vision that every drug can be made and every disease treated.

SOURCE WuXi AppTec